QIBA Ultrasound Shear Wave Speed (SWS) Biomarker Committee
Friday, January 23, 2015; 11 AM CT

call summary

Notes provided by Dr. Garra

In attendance

Brian Garra, MD (Co-Chair)  Steven Fick, PhD  Yasuo Miyajima, PhD
Timothy J. Hall, PhD (Co-Chair)  Gilles Guennette, RDMS, RDCS, RVT  Stephen Rosenzweig, PhD
Michael André, PhD  Ted Lynch, PhD  Matthew Urban, PhD
Paul Carson, PhD  Mike MacDonald, PhD  Michael Wang, PhD
Jun Chen, PhD  Ravi Managuli, PhD, RDMS  Keith Wear, PhD
Manish Dhyani, MD  Stephen McAleavey, PhD

RSNA

Joe Koudelik
Julie Lisiecki

Moderator: Dr. Garra

Agenda

- Review of previous minutes
- Review of Reorganization – Brian and Tim (post organization chart here)
- Summary of just completed QIBA Steering Committee meeting – Brian Tim and Paul
- Review of Projects Underway and Timelines (post Gantt chart if available)—Tim and Brian
- Discussion of Potential Publications and other deliverables. —All
- Phase I and II phantom study status. —All
- Other
- Adjourn

Discussion

1. Review of previous minutes—no additions or corrections were suggested.

2. Review of Reorganization – Brian and Tim (post organization chart here)—BSG summarized the new organization chart explaining the changes. The US coordinating committee will have a broader membership across the various subspecialty groups in ultrasound so that a balanced method of selecting new US biomarkers is achieved. The need for newly appointed coordinating committee members to attend the AIUM meeting in March was stressed by Dr Carson. Some potential biomarkers were also mentioned including some detailed mention of contrast biomarkers, Doppler biomarkers and volumetric biomarkers. The question of what biomarker related to US contrast agents was also raised.

3. Summary of just completed QIBA Steering Committee meeting – Brian Tim and Paul—the just completed meeting of the QIBA Steering Committee was reviewed by BSG with additional comments by Tim Hall and Paul Carson. The fact that NIBIB application for funding was discussed at the Steering committee prompted a suggestion by Tim Hall that members of the US committee should start thinking about what projects to ask for funding on in the next funding cycle.

4. The possibility of AIUM support for some of the US biomarker activities was mentioned including support for meetings and icons, support for phantoms and even support for a new biomarker effort. AIUM previously funded the interlab comparison for backscatter and attenuation and with board support QIBA activities could also be funded. The need to pick biomarkers of interest to AIUM board members was mentioned as was the interest the AIUM executive director, Carmine, has in US contrast.
5. Other steering committee agenda items such as profile production process, compliance, and a proposal for a governance committee that would set procedures for periodic document review and other processes that concern all committees were briefly summarized. Garra, Dhyani and Samir will meet this afternoon to work further on the US SWS profile.

6. The QIDW or data warehouse for QIBA data and images was introduced. Manish Dhyani mentioned that some pilot data had already been uploaded and that Kathy Andriole who heads the project on data warehouse development will be meeting with Dhyani and Anthony Samir to hash out procedures for upload and organization of US QIBA data—and the method for deidentification of the data.

7. Review of Projects Underway and Timelines (post Gantt chart if available)—Tim and Brian—this item was deferred until a proper Gantt chart can be produced. The review of all projects will occur at the next meeting where an attempt to place firm timelines on projects papers and other deliverables will be made.

8. Discussion of Potential Publications and other deliverables.—All—The phase one phantom study paper was first discussed. Tim Hall noted that a group of independent statisticians at Duke will be reviewing the previous analysis performed by Andy Milkowski to confirm those findings and suggest other potential analysis methods. Other potential publication subjects include: phase II phantom results, simulation development and testing on various FEA packages and clinical software, simulations of phantoms, processing parameters and techniques that affect SWS, and standard method of assessing viscoelasticity derived from the phantom and simulation work. Clinical paper topics include reporting the results of the ongoing clinical studies at MGH, and the elasticity case reporting form. The need to make the form consistent and with the RSNA structured reporting form in the works. This will be discussed this afternoon as part of the profile discussion. The need to post the forms on the QIBA wiki for others to use was stressed.

9. Phase I and II phantom study status.—All — The locations of the phantoms was discussed. BSG still needs the phase one phantoms and those will be supplied by MGH. These arrangements will be made off line. The late tests of the phase 1 phantoms will not be reported in the paper on the subject because of differences in data acquisition.

10. Other: Paul Carson pointed out that papers by individual groups are to be encouraged especially if a paper is possibly delayed by forming a collaboration.

11. Adjourn—at 1:03 PM

Upcoming Schedule – (Calls Friday at 11 am CT):

- February 6th System Dependencies & Phantom Task Force - (Dr. Palmeri’s rotation)
- February 13th US SWS Biomarker Ctte - (Dr. Hall’s rotation)
- February 20th System Dependencies & Phantom Task Force - (Dr. Wear’s rotation)
- February 27th Clinical Task Force - (Dr. Samir)